- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Lantheus Medical to Begin Phase 3 Trial of Injection Agent for CAD
Lantheus Medical Imaging Inc. has received a Special Protocol Assessment (SPA) approval for a Phase 3 clinical trial for the assessment of myocardial perfusion using PET imaging of an injection agent in patients with suspected coronary artery disease.
Lantheus Medical Imaging Inc. has received a Special Protocol Assessment (SPA) approval for a Phase 3 clinical trial for the assessment of myocardial perfusion using PET imaging of an injection agent in patients with suspected coronary artery disease.
The company plans to start the first of two planned trials of flurpiridaz F-18 in the second quarter of 2011. An SPA means the company’s proposed trial protocol is acceptable for approval.
“We believe that flurpiridaz F-18 can improve the diagnosis and evaluation of coronary artery disease, ultimately reducing the need for additional medical tests and procedures,” Lantheus president and CEO Don Kiepert said in a statement.
Data from a preliminary Phase 2 trial showed that PET imaging with flurpiridaz F-18 provided better image quality than technetium-99m sestamibi singe photon emission computer tomography (SPECT), which is the current standard for noninvasive detection of CAD, according to the company. A full data set from the Phase 2 clinical trial will be presented in May at the Nuclear Cardiology and Cardiac CT Conference.
The goal of the Phase 3 trial is to assess the sensitivity and specificity of flurpiridaz F-18 injection PET myocardial perfusion imaging in about 1,350 patients with known or suspected CAD at about 100 clinical sites.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
